---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-089235"
form_type: "8-K"
ticker: "SNDX"
cik: "0001395937"
company_name: "Syndax Pharmaceuticals Inc"
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T13:43:57.465837+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Syndax Q2 net loss $68.1M, revumenib PDUFA extended to Dec 26, 2024

## Summary
- Net loss of $68.1M ($0.80/sh) vs $44.6M ($0.64/sh) in Q2 2023; cash $454.6M as of June 30.
- R&D expenses $48.7M, SG&A $29.1M; FY2024 opex guidance $355-375M with sufficient capital through 2026.
- Revumenib NDA for R/R KMT2Ar leukemia PDUFA extended to Dec 26, 2024; AUGMENT-101 mNPM1 AML data expected 4Q24.
- Axatilimab BLA for chronic GVHD under Priority Review with PDUFA date Aug 28, 2024.
- Appointed Dr. Aleksandra Rizo to Board of Directors in May 2024.

## SEC filing metadata
- accession: 0000950170-24-089235
- form_type: 8-K
- ticker: SNDX
- cik: 0001395937
- company_name: Syndax Pharmaceuticals Inc
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1395937/000095017024089235/0000950170-24-089235-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1395937/000095017024089235/sndx-20240801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-089235
- JSON: https://secwatch.observer/filing/0000950170-24-089235.json
- Plain text: https://secwatch.observer/filing/0000950170-24-089235.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.